Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NLSP
DateHeureSourceTitreSymboleSociété
10/03/202512h00PR Newswire (US)NLS Pharmaceutics CEO Issues Letter to ShareholdersNASDAQ:NLSPNLS Pharmaceutics Ltd
27/02/202513h00PR Newswire (US)NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist PlatformNASDAQ:NLSPNLS Pharmaceutics Ltd
25/02/202515h05PR Newswire (US)Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes TreatmentNASDAQ:NLSPNLS Pharmaceutics Ltd
10/02/202513h30PR Newswire (US)NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 TherapiesNASDAQ:NLSPNLS Pharmaceutics Ltd
31/01/202513h30PR Newswire (US)Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsNASDAQ:NLSPNLS Pharmaceutics Ltd
30/01/202513h30PR Newswire (US)NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingNASDAQ:NLSPNLS Pharmaceutics Ltd
28/01/202513h30PR Newswire (US)NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependenceNASDAQ:NLSPNLS Pharmaceutics Ltd
16/01/202515h32PR Newswire (US)Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSNASDAQ:NLSPNLS Pharmaceutics Ltd
08/01/202513h42PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share PriNASDAQ:NLSPNLS Pharmaceutics Ltd
30/12/202413h30PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerNASDAQ:NLSPNLS Pharmaceutics Ltd
04/12/202419h15PR Newswire (US)NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketNASDAQ:NLSPNLS Pharmaceutics Ltd
27/08/202422h01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:NLSPNLS Pharmaceutics Ltd
26/08/202422h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
15/07/202415h16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NLSPNLS Pharmaceutics Ltd
14/06/202314h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
05/05/202322h37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
01/05/202322h31Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
24/02/202313h56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/02/202312h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
23/01/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/01/202322h03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:NLSPNLS Pharmaceutics Ltd
21/12/202222h03Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NLSPNLS Pharmaceutics Ltd
16/12/202222h58Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
10/06/202222h44Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202218h15TipRanksBrookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
04/05/202220h25TipRanksBrookline Capital Markets Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/04/202222h49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/04/202214h18Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NLSPNLS Pharmaceutics Ltd
17/03/202215h36TipRanksMaxim Group Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
01/11/202113h31Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NLSP

Dernières Valeurs Consultées

Delayed Upgrade Clock